Nisa Investment Advisors’s Akoya BioSciences AKYA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-594
| Closed | -$772 | – | 2985 |
|
|
2025
Q2 | $772 | Buy |
594
+449
| +310% | +$540 | ﹤0.01% | 2788 |
|
|
2025
Q1 | $202 | Sell |
145
-75
| -34% | -$164 | ﹤0.01% | 2922 |
|
|
2024
Q4 | $504 | Buy |
220
+169
| +331% | +$448 | ﹤0.01% | 2831 |
|
|
2024
Q3 | $139 | Buy |
51
+27
| +113% | +$66 | ﹤0.01% | 2887 |
|
|
2024
Q2 | $56 | Sell |
24
-6,041
| -100% | -$19.3K | ﹤0.01% | 2901 |
|
|
2024
Q1 | $28.4K | Buy |
6,065
+6
| +0.1% | +$31 | ﹤0.01% | 1786 |
|
|
2023
Q4 | $29.6K | Buy |
6,059
+6,000
| +10,169% | +$24.9K | ﹤0.01% | 1758 |
|
|
2023
Q3 | $274 | Buy |
+59
| New | +$339 | ﹤0.01% | 2624 |
|
|
2023
Q1 | – | Sell |
-2,000
| Closed | -$19K | – | 2515 |
|
|
2022
Q4 | $19K | Hold |
2,000
| – | – | ﹤0.01% | 2066 |
|
|
2022
Q3 | $28K | Hold |
2,000
| – | – | ﹤0.01% | 1949 |
|
|
2022
Q2 | $26K | Buy |
+2,000
| New | +$20.7K | ﹤0.01% | 1963 |
|
Nisa Investment Advisors's AKYA Position: Q3 2025 in Review
Nisa Investment Advisors sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 594 shares — an estimated $772 sold.
Nisa Investment Advisors first reported a position in AKYA in Q2 2022 and held it in 11 quarters. The position peaked at $29.6K in Q4 2023. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.
- Nisa Investment Advisors reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
- Nisa Investment Advisors sold 594 Akoya BioSciences shares in Q3 2025, an estimated $772.
- Nisa Investment Advisors first reported a position in Akoya BioSciences in Q2 2022 and held it in 11 quarters.
- Nisa Investment Advisors's Akoya BioSciences position peaked at $29.6K in Q4 2023.
- 0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.
Based on Nisa Investment Advisors's 13F filing for Q3 2025, filed 23 Oct 2025.